ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (
NYSE: NVO) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue OpportunitiesPALM BEACH, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report, Grand View Research said that the global diabetic retinopathy market size was estimated at USD 9.48 billion in 2024 and is expected to grow at a CAGR of 6.4% from 2025 to 2030. One of the main factors expected to fuel market expansion is the growing incidence of diabetes in older individuals and the rising prevalence of blindness caused by diabetes. The introduction of novel diagnostic technologies and treatments and the increased awareness are driving the market expansion. The report said: “Diabetes is a globally prevalent health concern. It can result in Diabetic Retinopathy (DR), which is caused by damage to the blood vessels in the retina. DR leads to blurred vision and vision loss in most cases. International Diabetes Federation estimates that 1 in 8 adults will be living with diabetes in 2050. It also states urbanization, an aging population, decreasing physical activity, and the growing prevalence of obesity are some of the key aspects contributing to the rise in type 2 diabetes. DR is a serious microvascular complication of type I and type II diabetes. It is often caused by prolonged high blood sugar levels that damage the blood vessels in the retina. It can progress to sight-threatening stages, which can cause blindness and visual impairment if not treated. According to a report published by the WHO, DR is responsible for 4.8% of the 37 million blindness cases in the world. The prevalence of this condition in the U.S. is expected to increase rapidly. Despite all the necessary measures adopted by the diabetic population, DR can lead to permanent blindness based on the disease stage and severity of the condition. Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tandem Diabetes Care, Inc. (
NASDAQ: TNDM), Novo Nordisk A/S (
NYSE: NVO), Insulet Corporation (
NASDAQ: PODD), Medtronic plc (
NYSE: MDT).
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo NordiskFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their Options
NVO Deadline: Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Novo Nordisk A/S (
NYSE: NVO) between November 2, 2022 and December 19, 2024. Novo describes itself as a “healthcare company, focused on the research, development, manufacturing, and distribution of pharmaceutical productions globally.”
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the FirmNEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Novo Nordisk A/S (“Novo” or the “Company”) (
NYSE: NVO) for violations of the federal securities laws on behalf of investors who purchased or acquired Novo common stock between November 2, 2022 to December 19, 2024, inclusive (the “Class Period”).
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ESSA, Cardlytics, Novo Nordisk, and Crocs and Encourages Investors to Contact the FirmNEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ESSA Pharma Inc. (
NASDAQ:EPIX), Cardlytics, Inc. (
NASDAQ:CDLX), Novo Nordisk A/S (
NYSE:NVO), and Crocs, Inc. (
NASDAQ: CROX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo NordiskFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo NordiskFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the FirmNEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Novo Nordisk A/S (“Novo” or the “Company”) (
NYSE: NVO) for violations of the federal securities laws on behalf of investors who purchased or acquired Novo common stock between November 2, 2022 to December 19, 2024, inclusive (the “Class Period”).
NVO Shareholders Have an Opportunity to Lead the Class Action Against Novo Nordisk A/S – Contact Shareholder Rights Law Firm Robbins LLP for InformationSAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Novo Nordisk A/S (
NYSE: NVO) securities between November 2, 2022 and December 19, 2024. Novo is a healthcare company, focused on the research, development, manufacturing, and distribution of pharmaceutical productions globally.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo NordiskFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVOFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TELUS International, Novo Nordisk, Micron, and ModivCare and Encourages Investors to Contact the FirmNEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of TELUS International (Cda) Inc. (
NYSE:TIXT), Novo Nordisk A/S (
NYSE:NVO), Micron Technology, Inc. (
NASDAQ:MU), and ModivCare, Inc. (
NASDAQ: MODV). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo NordiskFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the FirmNEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Novo Nordisk A/S (“Novo” or the “Company”) (
NYSE: NVO) for violations of the federal securities laws on behalf of investors who purchased or acquired Novo common stock between November 2, 2022 to December 19, 2024, inclusive (the “Class Period”).
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo NordiskFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cardlytics, Novo Nordisk, Micron, and ModivCare and Encourages Investors to Contact the FirmNEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Cardlytics, Inc. (
NASDAQ:CDLX), Novo Nordisk A/S (
NYSE:NVO), Micron Technology, Inc. (
NASDAQ:MU), and ModivCare, Inc. (
NASDAQ: MODV). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the FirmNEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Novo Nordisk A/S (“Novo” or the “Company”) (
NYSE: NVO) for violations of the federal securities laws on behalf of investors who purchased or acquired Novo common stock between November 2, 2022 to December 19, 2024, inclusive (the “Class Period”).
